Crossmark

Impact of Tafamidis on [99mTc]Tc-pyrophosphate Scintigraphy in Ala97Ser Hereditary Transthyretin amyloid cardiomyopathy: significant initial reduction with stable Long-Term effects

Crossref DOI link: https://doi.org/10.1007/s00259-025-07079-4

Published Online: 2025-01-13

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yu, An-Li

Chen, Yi-Chieh

Tsai, Cheng-Hsuan

Chao, Chi-Chao

Su, Mao-Yuan

Shun, Chia-Tung

Hsueh, Hsueh-Wen

Juang, Jyh-Ming Jimmy

Lee, Ming-Jen

Tseng, Ping-Huei

Hsieh, Sung-Tsang

Cheng, Mei-Fang https://orcid.org/0000-0002-9359-0606
Lin, Yen-Hung
Funding

Funding for this research was provided by:

Pfizer (Pfizer)
License Information

Text and Data Mining valid from 2025-01-13

Version of Record valid from 2025-01-13
More Information

Article History

Received: 1 August 2024

Accepted: 4 January 2025

First Online: 13 January 2025

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of National Taiwan University Hospital (No. 201912120MSA, 202208006RIND).

: Informed consent was obtained from all individual participants included in the study.

: Yen-Hung Lin has received research grant support from Pfizer. The other authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Document is current

Any future updates will be listed below